BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 21289624)

  • 1. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
    Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
    Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis.
    Qin J; Wu SP; Creighton CJ; Dai F; Xie X; Cheng CM; Frolov A; Ayala G; Lin X; Feng XH; Ittmann MM; Tsai SJ; Tsai MJ; Tsai SY
    Nature; 2013 Jan; 493(7431):236-40. PubMed ID: 23201680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
    Gerke TA; Martin NE; Ding Z; Nuttall EJ; Stack EC; Giovannucci E; Lis RT; Stampfer MJ; Kantoff PW; Parmigiani G; Loda M; Mucci LA
    Prostate; 2015 Dec; 75(16):1926-33. PubMed ID: 26469352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
    Sun B; Fan Y; Yang A; Liang L; Cao J
    J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposing roles of TGFβ and BMP signaling in prostate cancer development.
    Lu X; Jin EJ; Cheng X; Feng S; Shang X; Deng P; Jiang S; Chang Q; Rahmy S; Chaudhary S; Lu X; Zhao R; Wang YA; DePinho RA
    Genes Dev; 2017 Dec; 31(23-24):2337-2342. PubMed ID: 29352019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
    Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
    Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predicator of metastatic cancer identified.
    Printz C
    Cancer; 2011 Jul; 117(13):2829. PubMed ID: 21692044
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
    Yang X; Zhang Q; Li S; Devarajan R; Luo B; Tan Z; Wang Z; Giannareas N; Wenta T; Ma W; Li Y; Yang Y; Manninen A; Wu S; Wei GH
    J Exp Clin Cancer Res; 2023 Aug; 42(1):198. PubMed ID: 37550764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin.
    Qiao W; Li AG; Owens P; Xu X; Wang XJ; Deng CX
    Oncogene; 2006 Jan; 25(2):207-17. PubMed ID: 16170355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.
    Ju X; Casimiro MC; Gormley M; Meng H; Jiao X; Katiyar S; Crosariol M; Chen K; Wang M; Quong AA; Lisanti MP; Ertel A; Pestell RG
    Cancer Res; 2014 Jan; 74(2):508-19. PubMed ID: 24282282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer.
    Alioui A; Dufour J; Leoni V; Loregger A; Moeton M; Iuliano L; Zerbinati C; Septier A; Val P; Fouache A; Russo V; Volle DH; Lobaccaro JA; Zelcer N; Baron S
    Nat Commun; 2017 Sep; 8(1):445. PubMed ID: 28874658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse.
    Teng Y; Sun AN; Pan XC; Yang G; Yang LL; Wang MR; Yang X
    Cancer Res; 2006 Jul; 66(14):6972-81. PubMed ID: 16849541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMP suppresses PTEN expression via RAS/ERK signaling.
    Beck SE; Carethers JM
    Cancer Biol Ther; 2007 Aug; 6(8):1313-7. PubMed ID: 18059158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Transition Zone Showing Highly Discontinuous or Alternating Levels of Stem Cell and Proliferation Markers Characterizes the Development of PTEN-Haploinsufficient Colorectal Cancer.
    Arvai KJ; Hsu YH; Lee LA; Jones D
    PLoS One; 2015; 10(6):e0131108. PubMed ID: 26098881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.
    Bjerke GA; Pietrzak K; Melhuish TA; Frierson HF; Paschal BM; Wotton D
    PLoS One; 2014; 9(3):e92800. PubMed ID: 24651496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
    Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
    Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.